MELFIAT-105 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Melfiat-105, and what generic alternatives are available?
Melfiat-105 is a drug marketed by Numark and is included in one NDA.
The generic ingredient in MELFIAT-105 is phendimetrazine tartrate. There are five drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the phendimetrazine tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Melfiat-105
A generic version of MELFIAT-105 was approved as phendimetrazine tartrate by VIRTUS on December 31st, 1969.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MELFIAT-105?
- What are the global sales for MELFIAT-105?
- What is Average Wholesale Price for MELFIAT-105?
Summary for MELFIAT-105
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 21 |
Patent Applications: | 1,902 |
DailyMed Link: | MELFIAT-105 at DailyMed |
US Patents and Regulatory Information for MELFIAT-105
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Numark | MELFIAT-105 | phendimetrazine tartrate | CAPSULE, EXTENDED RELEASE;ORAL | 087487-001 | Oct 13, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |